Cocrystal pharma presents preclinical data from covid-19 antiviral programs and outlines near-term clinical plans at the world antiviral congress 2021

Unveils designs for phase 1 and 2 stud ies with intranasal/pulmonary and oral sars-cov-2 protease inhibitors ; trial initiations expected in 2022
COCP Ratings Summary
COCP Quant Ranking